Abstract 12: Characterizing KRAS G12C and other mutations in plasma ctDNA from patients with lung cancer
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Cancer Research"
DOI: 10.1158/1557-3265.advprecmed20-12
Abstract: Background: KRAS is the most common oncogene in lung cancers, but despite decades of intense research, there are no FDA-approved drugs targeting these cancers. Recent recognition that KRAS G12C harbors a binding pocket near the… read more here.
Keywords: ctdna; non g12c; patients kras; cancer ... See more keywords